Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q4 2018 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q4 2018 earnings summary

9 Nov, 2026

Executive summary

  • Clinical-stage biopharmaceutical business developing programmed T-cell therapies; five programs span six hematological and solid-tumor indications, with no approved products or product-sales revenue.

  • Four Phase 1/2 proof-of-concept trials in hematological cancers were targeted for completion in 2019; worldwide commercial rights held across the therapy portfolio.

Financial highlights

  • FY2018 operating loss was £40.4m vs. £18.5m in FY2017; net loss was £31.1m vs. £15.6m.

  • FY2018 R&D expense was £24.6m vs. £12.9m; administrative expense was £16.8m vs. £7.2m.

  • Other operating income was £1.0m; finance income £4.1m; income tax credit £5.2m; loss before tax £36.3m.

  • Cash and cash equivalents were £189.3m at September 30, 2018 vs. £102.3m a year earlier; total assets were £217.7m.

Outlook and guidance

  • Existing cash was expected to fund current and planned operating expenses and capex into calendar 2021, subject to assumptions; forecasts through 2020 supported the going-concern basis.

  • Significant losses and expenses were expected to continue as clinical development, regulatory work, manufacturing capacity and commercialization preparations advanced.

  • Proof-of-concept phases of four Phase 1/2 hematological cancer trials were expected in 2019; AUTO6 NG trial initiation was planned for 2020.

  • Additional financing may be needed; possible sources include equity, debt, collaborations or strategic transactions, with potential dilution or rights concessions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics